Editing Johnson & Johnson (section)

==== Janssen COVID-19 vaccine ====
{{main|Janssen COVID-19 vaccine}}
In June 2020, Johnson & Johnson and the [[National Institute of Allergy and Infectious Diseases]] (NIAID) confirmed its intention to start a clinical trials of J&J's vaccine in September 2020, with the possibility of Phase 1/2a human clinical trials starting at an accelerated pace in the second half of July.<ref>{{Cite web|last=Coleman|first=Justine|date=June 10, 2020|title=Final testing stage for potential coronavirus vaccine set to begin in July|url=https://thehill.com/policy/healthcare/501999-final-testing-stage-for-coronavirus-vaccine-could-begin-in-july-report|access-date=June 11, 2020|website=[[The Hill (newspaper)|The Hill]]|language=en}}</ref><ref>{{Cite news|title=Moderna, AstraZeneca and J&J coronavirus shots rev up for NIH tests beginning in July: WSJ|url=https://www.fiercepharma.com/vaccines/nih-preps-late-stage-studies-moderna-az-and-j-j-coronavirus-vaccines-wsj|access-date=June 11, 2020|newspaper=Fierce Pharma|date=June 10, 2020 |language=en}}</ref><ref>{{Cite news|title=Johnson & Johnson to start human testing of COVID-19 vaccine next week|url=https://www.fiercepharma.com/vaccines/j-j-to-start-human-testing-covid-19-vaccine-next-week-exec|access-date=July 20, 2020|newspaper=Fierce Pharma|date=July 16, 2020 |language=en}}</ref>

On August 5, 2020, the [[Federal government of the United States|US government]] agreed to pay more than $1&nbsp;billion to Johnson & Johnson (medical device company) for the production of 100 million doses of COVID-19 vaccine. As part of the agreed-upon deal, the U.S. can order up to 200&nbsp;million additional doses of SARS-CoV-2 vaccine.<ref>{{cite web|url=https://www.voanews.com/a/covid-19-pandemic_us-pay-johnson-and-johnson-1-billion-covid-19-vaccine/6193967.html|title=US to Pay Johnson and Johnson $1 Billion for COVID-19 Vaccine|access-date=August 5, 2020|website=Voice of America|date=August 5, 2020 }}</ref>

In September 2020, Johnson & Johnson started its 60,000-person phase 3 [[Adenoviridae|adenovirus]]-based vaccine trial.<ref>{{Cite press release|last=Johnson|first=Johnson &|title=Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate|url=https://www.prnewswire.com/news-releases/johnson--johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate-301136522.html|access-date=September 24, 2020|website=www.prnewswire.com|language=en}}</ref> The trial was paused on October 12, 2020, because a volunteer became ill,<ref>{{Cite news|last1=Hughes|first1=Virginia|last2=Thomas|first2=Katie|last3=Zimmer|first3=Carl|last4=Wu|first4=Katherine J.|date=October 12, 2020|title=Johnson & Johnson halts coronavirus vaccine trial because of sick volunteer.|language=en-US|work=[[The New York Times]]|url=https://www.nytimes.com/live/2020/10/12/world/coronavirus-covid|access-date=October 12, 2020|issn=0362-4331}}</ref> but the company said it found no evidence that the vaccine had caused the illness and announced on October 23, 2020, that it would resume the trial.<ref>{{Cite web|date=October 23, 2020|title=Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.|url=https://www.jnj.com/our-company/johnson-johnson-prepares-to-resume-phase-3-ensemble-trial-of-its-janssen-covid-19-vaccine-candidate-in-the-us|access-date=October 28, 2020|website=Johnson & Johnson|language=en}}</ref><ref>{{Cite web|last1=Edwards|first1=Erika|last2=Miller|first2=Sara G.|date=October 23, 2020|title=AstraZeneca, Johnson & Johnson resume late-stage Covid-19 vaccine trials|url=https://www.nbcnews.com/health/health-news/astrazeneca-johnson-johnson-resume-late-stage-covid-19-vaccine-trials-n1244579|access-date=October 28, 2020|website=[[NBC News]]|language=en}}</ref>

In April 2021, the company reported that its COVID-19 vaccine achieved $100&nbsp;million sales in the first quarter, accounting for less than 1% of its total revenue.<ref>{{Cite web|last=Lovelace|first=Berkeley Jr.|date=April 20, 2021|title=Johnson & Johnson reports $100 million in quarterly sales from Covid vaccine|url=https://www.cnbc.com/2021/04/20/johnson-johnson-jnj-earnings-q1-2021.html|access-date=April 29, 2021|website=[[CNBC]]|language=en}}</ref><ref>{{Cite news|last=Grant|first=Charley|date=April 20, 2021|title=Johnson & Johnson Shows Health Economy Is Nearing Full Strength|language=en-US|work=[[The Wall Street Journal]]|url=https://www.wsj.com/articles/johnson-johnson-shows-health-economy-is-nearing-full-strength-11618931401|access-date=April 29, 2021|issn=0099-9660}}</ref>